The Caucus was created to monitor and encourage the U.S.
government and private programs seeking to expand international
cooperation against drug abuse and narcotics trafficking, and
promote international compliance with narcotics control treaties,
including eradication. As a formal organization of the Senate, the
Caucus has the status of a standing committee. It has subpoena power
and is authorized to take testimony of witnesses and to produce
books, records, papers, and documents that it deems necessary. In
the past it has dealt with international cooperation, eradication,
trafficking, interdiction, border control, drug strategies,
assessments of Federal programs, and money laundering issues.
The Caucus has held numerous hearings over the years and has
issued a number of reports on U.S. narcotics control policy. The
primary responsibilities of the I.N.C.C. have involved monitoring of
compliance with international narcotics control treaties and
agreements, and oversight of U.S. counter narcotics policy and
activities.
Establishment
The United States Senate Caucus on International Narcotics
Control (also known as the Senate Drug Caucus) was originally
called the United States Commission on International Narcotics
Control, when it was established on August 16, 1985 by the Foreign
Relations Authorization Act for fiscal 1986 and 1987.1
Pursuant to the Legislative Branch Appropriations Act of 1986 (PL
99-151), the name of the Commission was changed to the United States
Senate Caucus on International Narcotics Control, effective November
13, 1985. (The House had requested the name change because it would
more accurately reflect the membership of the group, given that no
House Members were to be appointed to it.)
1 PL 99-93 (99
Stat. 455.).
Membership
The group's authorizing legislation (PL 99-93) provided that the
Commission draw its membership from the Senate and from experts in
the private sector. Specifically, the group was to be composed
of 12 members, seven Members of the U.S. Senate appointed by the
President of the Senate, and five members from the private sector
appointed by the president of the United States. Four of the
seven Senators, including one designated as Chairman, were to be
selected from the majority party after consultation with the
Majority Leader, and three, including the Member designated as
Co-Chairman, were to be selected from the minority party, after
consultation with the Minority Leader. The five Commission
members selected from the private sector were to be appointed by the
President after consultation with the Members of the appropriate
congressional committees. The appointment of private citizens
was discontinued after 1987 in accordance with the group's
redesignation as the U.S. Senate Caucus on International Narcotics
Control.
Current Members of Narcotics Caucus
Senator Dianne
Feinstein (D-CA) Chairman
Senator Charles E.
Grassley (R-IA) Co-Chairman
Senator
Jeff Sessions (R-AL)
Senator Charles Schumer (D-NY)
Senator Sheldon Whitehouse (D-RI)
111th Congress Legislation
109th Congress Legislation
S.103 The Combat Meth Act
S.1114 The Clean sports Act
S.2560 The Office of National Drug Control Policy Reauthorization Act
S.1137 Amend Anabolic Steroid Control Act to Include DHEA
S.Res.495 The National Vigil For Lost Promise
S.1960 Integrity In Professional Sports Act
S.529 United States Anti-Doping Agency Act
108th Congress Legislation